Fig. 1 · Structure

Documents & Downloads

Risperidone

Cat. No. A10797 CAS 106266-06-2
Risperidone(Risperdal) is an atypical antipsychotic used to treat schizophrenia (including adolescent schizophrenia), schizoaffective disorder, the mixed and manic states associated with bipolar disorder, and irritability in children with autism.

In Stock

Publications for Risperidone

2 publications citing this product

  1. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
  2. Jaime Osuna-Luque, .et al. , J Exp Neurosci, 2018, 12: 1179069518798628 PMID: 30245571

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Risperidone binds an inactive-state human dopamine D2 receptor in a 2.9 Å engineered-receptor structure. Its tertiary amine contacts Asp114, and its benzisoxazole group occupies a deep hydrophobic pocket. Membrane binding experiments support a role for pocket residues in slow dissociation: estimated residence time was 233 min for wild-type D2, 28 min for W100A and 6 min for L94A/I184A; individual L94A and I184A mutations did not significantly change dissociation. These assay estimates do not establish clinical duration of action. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
5-HT2A ki 0.17nM
α2c-adrenergicreceptor ki 1.3nM
D2receptor ki 3.57nM
D3receptor ki 3.6nM
D2LReceptor ki 4.16nM
D4receptor ki 4.66nM
D2SReceptor ki 4.73nM
α1A-adrenergicreceptor ki 5nM
5-HT7 ki 6.6nM
α1B-adrenergicreceptor ki 9nM
5-HT2C ki 12nM
5-HT1B ki 14.9nM
α2a-adrenergicreceptor ki 16.5nM
H1receptor ki 20.1nM
5-HT2B ki 61.9nM
5-HT1D ki 84.6nM
α2b-adrenergicreceptor ki 108nM
H2receptor ki 120nM
5-HT5A ki 206nM
5-HT5A ki 206nM
D1receptor ki 244nM
D5receptor ki 290nM
5-HT1A ki 423nM
5-HT6 ki 2060nM

24 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
CHO IC50 34.2 μM Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits [PMID: 23812503]
HEK293 IC50 1.6 μM Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 102000 nM Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA [PMID: 21300721]
HEK293 IC50 11 μM Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 125 μM Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit [PMID: 22761000]
HEK293 IC50 291 μM Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 581 nM Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay [PMID: 23675993]
Ventricular myocyte IC50 116 μM Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes [PMID: 22761000]
Ventricular myocyte IC50 73 μM Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes [PMID: 22761000]
Ventricular myocyte IC50 73000 nM Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes [PMID: 21300721]
WI-38 EC50 > 25 μM Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay [PMID: 17893158]
WI-38 CC50 25 μM Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay [PMID: 17893158]

12 records · Scroll to view more

In Vitro Studies

Risperidone-bound engineered human D2 receptor structure

Biochemical assay · Engineered human D2 long receptor with T4 lysozyme fusion and I122A/L375A/L379A thermostabilizing mutations. [1]

A 2.9 Å X-ray structure shows an inactive-state D2 receptor complex. The ligand tertiary amine contacts Asp114, while the benzisoxazole group occupies a deep hydrophobic pocket. The engineered construct and crystal environment limit direct extrapolation to native receptor dynamics.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Diffraction resolution of the risperidone-bound receptor complexresolution 2.90 Å[1]

Literature-Reported Treatment Conditions

Method
Risperidone-bound receptor purified and crystallized in lipidic cubic phase; structural endpoint.
Reported limits
A single treatment concentration/duration is not applicable to this multistage structural preparation. No salt, analytical purity or supplier lot specified in the read methods.
Methods and source locations

Compound reported in the paper: Risperidone

Compound-level evidence for risperidone; no validation of A10797 or an Adooq lot.

Main text structural results; Figures 1–2 and captions; Extended Data Tables 1–2; Methods: Protein engineering, purification, crystallization and structure determination

Diffraction resolution of the risperidone-bound receptor complex: X-ray diffraction; data merged from 20 crystals. — Main text structural results; Figure 1; Extended Data Table 2

D2 receptor pocket mutations alter risperidone binding kinetics

Biochemical assay · HEK293T membrane preparations transiently expressing human D2 long receptor, wild type or pocket mutants. [1]

Competitive binding kinetics estimated slower dissociation from wild-type D2 than from W100A or the L94A/I184A double mutant. Individual L94A and I184A effects on dissociation were not significant. Residence time is 1/koff, not an exposure duration or clinical half-life.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Wild-type risperidone dissociation and residence timekoff; residence time 0.0043 ± 0.0003 min−1; 233 min[1]
Mutant risperidone dissociation and residence timekoff; residence time W100A: 0.036 ± 0.0022 min−1; 28 min. L94A/I184A: 0.16 ± 0.05 min−1; 6 min. L94A: 0.0072 ± 0.0029 min−1; 139 min (n.s.). I184A: 0.0054 ± 0.002 min−1; 185 min (n.s.).[1]

Literature-Reported Treatment Conditions

Treatment concentration
Risperidone 1, 10 and 100 nM in Extended Data Figure 6a–g; radioligand 0.8–1.0 nM in Table 1 footnote.
Exposure duration
Time courses; Extended Data Figure 6a–g plots through 120 min.
Method
Membrane competitive kinetic binding at room temperature; rates estimated with the Motulsky–Mahan competitive-binding model.
Co-treatment
Radioligand assay component, not a therapeutic combination. Nonspecific binding defined with 10 µM nemonapride.
Reported limits
Risperidone solvent not specified in the read kinetic methods; no salt or lot validation. Time points are assay sampling times.
Methods and source locations

Compound reported in the paper: Risperidone

Compound-level evidence for risperidone; no validation of A10797 or an Adooq lot.

Table 1 and footnote; Extended Data Figure 6a–g and caption; Methods: Ligand Association and Dissociation Radioligand Binding Assays

Wild-type risperidone dissociation and residence time: Competitive kinetics with [3H]-N-methylspiperone; room temperature; four independent experiments; ± denotes SEM for koff. — Table 1, DRD2 wild-type row and footnote; Ligand Association and Dissociation Radioligand Binding Assays

Mutant risperidone dissociation and residence time: Four independent experiments; koff mean ± SEM. Table 1 unpaired two-tailed t-test versus WT: W100A p=0.007; double mutant p=0.005. — Table 1, W100A, L94A, I184A and L94A/I184A rows and footnote

In Vivo Studies

In wild-type C. elegans, developmental exposure to risperidone reduced gentle-touch responses and pharyngeal pumping at L4. At 300 µM in agar containing 1% DMSO, both endpoints differed from matched vehicle controls (P < .001). Each assay included at least three independent experiments with at least ten worms per experiment. These nematode behavioral effects do not establish mammalian efficacy or identify a unique receptor target. [2]

Direct developmental exposure changes wild-type nematode behavior

Animal study · Wild-type N2 Bristol Caenorhabditis elegans, assayed as L4 hermaphrodites. [2]

Risperidone exposure during development reduced the number of positive gentle-touch responses and pharyngeal pumping at L4 compared with 1% DMSO controls. These are whole-animal neuromuscular phenotypes and do not establish mammalian antipsychotic efficacy or a unique receptor mechanism.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Positive responses to ten alternating anterior/posterior gentle touchesdirection and reported significance Reduced response at 150, 250, 300 and 350 µM; **P < .01 at 150 µM, ***P < .001 at 250–350 µM versus 1% DMSO.[2]
Pharyngeal pumping ratedirection and reported significance Reduced at 300 µM; P < .001 versus 1% DMSO.[2]

Conditions shared by the study groups

Route
Environmental exposure in agar plates
Frequency
Present in developmental growth medium
Treatment course
Egg/L1 to late L4
Vehicle
1% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Risperidone 300 µM versus vehicle
300 µM in agar medium
Matched medium with 1% DMSO and no antipsychoticReduced gentle-touch response and pharyngeal pumping; P < .001 for both in Figures 1A and 3.[2]
Risperidone 300 µM versus vehicle
Model: N2 wild-type C. elegans, late L4.
Reported limits: Elapsed exposure hours and internal risperidone concentrations not specified.
Methods and source locations

Compound reported in the paper: Risperidone; Compound label in the paper: Risp

Evidence for reported risperidone powder in nematodes, without supplier-specific attribution or A10797 lot validation.

Table 1; Methods: Risperidone and aripiprazole assays, Behavioral assays, Statistical analysis; Figures 1A and 3 and captions

Positive responses to ten alternating anterior/posterior gentle touches: Blinded behavioral scoring; at least 3 independent experiments with at least 10 L4 worms each; bars mean ± SEM; one-way ANOVA. No exact bar means inferred. — Figure 1A and caption; Results: Risperidone and aripiprazole alter the touch response

Pharyngeal pumping rate: Recorded contractions counted offline in slow motion and expressed as pumps/min; at least 3 independent experiments with at least 10 L4 worms each; bars mean ± SEM; one-way ANOVA. Exact means not tabulated in the adopted figure. — Figure 3 and caption; Results: Risperidone and aripiprazole modify the pharyngeal pumping rate

Risperidone 300 µM versus vehicle · Table 1; Methods: drug assays and behavioral assays; Figures 1A and 3

Specifications

Manufacturer Adooq Bioscience
CAS Number 106266-06-2
Formula C23H27FN4O2
Molecular Weight 410.5
Synonyms R 64 766; Risperdal
SMILES
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 4 mg/mL (9.74 mM)
Water Insoluble
Ethanol 4 mg/mL (9.74 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wang S, Che T, Levit A, et al. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature (2018). PMID: 29466326 DOI: 10.1038/nature25758 Source material
  2. [2] Osuna-Luque J, Rodríguez-Ramos Á, Gámez-Del-Estal MDM, et al. Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole. Journal of experimental neuroscience (2018). PMID: 30245571 DOI: 10.1177/1179069518798628 Source material

Publications

2 publications citing this product

  1. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967
  2. Jaime Osuna-Luque, .et al. , J Exp Neurosci, 2018, 12: 1179069518798628 PMID: 30245571

Added to your cart

View Cart Checkout
Loading...